← Back to Search

Positron Emission Tomography for Prostate Cancer (PSMA-dRT Trial)

Phase 3
Waitlist Available
Led By Jeremie Calais
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Or cT-stage >= 2b
Adult male 18 years or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years after the date of randomization
Awards & highlights

PSMA-dRT Trial Summary

This trial studies whether PSMA-based radiation therapy improves outcomes for prostate cancer compared to standard radiation therapy.

Eligible Conditions
  • Prostate Cancer

PSMA-dRT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

PSMA-dRT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years after the date of randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years after the date of randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Success rate of definitive radiation therapy (dRT)
Secondary outcome measures
Change in initial treatment intent
Loco-regional progression free survival
Metastasis-free survival after initiation of radiation therapy (RT)
+3 more

PSMA-dRT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm II (18F-DCFPyL, PET/CT, dRT)Experimental Treatment4 Interventions
162 Patient undergoes PSMA PET with 18F-DCFPyL for dRT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. Patients then undergo dRT at the discretion of the treating radiation oncologist, who receives PSMA PET results and images. No other primary treatment can be given before RT.
Group II: Arm I (dRT)Active Control1 Intervention
150 Patients undergo standard dRT at the discretion of the treating radiation oncologist. Patient does not undergo PSMA PET for RT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. No other primary treatment can be given before dRT. If a patient assigned to the control arm undergo a PSMA PET scan at another institution he will be discontinued from the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Computed Tomography
2017
Completed Phase 2
~2790
Positron Emission Tomography
2008
Completed Phase 2
~2260
Radiation Therapy
2017
Completed Phase 3
~7250

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor
358 Previous Clinical Trials
26,022 Total Patients Enrolled
39 Trials studying Prostate Cancer
4,000 Patients Enrolled for Prostate Cancer
Progenics Pharmaceuticals, Inc.Industry Sponsor
32 Previous Clinical Trials
4,886 Total Patients Enrolled
18 Trials studying Prostate Cancer
2,334 Patients Enrolled for Prostate Cancer
Jeremie CalaisPrincipal InvestigatorUCLA / Jonsson Comprehensive Cancer Center
7 Previous Clinical Trials
1,319 Total Patients Enrolled
4 Trials studying Prostate Cancer
1,087 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we currently enrolling new participants for this research project?

"According to the clinicaltrials.gov website, this clinical trial is not currently looking for participants. The study was initially posted on 2020-08-14, and has not been updated since 2022-02-10. However, there are 1274 other trials that are actively recruiting patients."

Answered by AI

What is the government organization's stance on Radiation Therapy?

"There is some evidence of efficacy from prior clinical trials and multiple rounds of data supporting safety, so our team at Power gave Radiation Therapy a score of 3."

Answered by AI
~12 spots leftby Mar 2025